Health IT company Episource confirmed a ransomware attack of its network exposed data from payer and provider customers alike, with details such as medical diagnoses and treatments possibly stolen by nefarious actors. 

The information was deleted to comply with an executive order from President Trump that censored content related to “gender ideology.” However, a federal judge has ordered the content restored as a court battle looms. 

American Medical Association President Bruce Scott, MD, explains the growing issues with insurance prior authorization impacting patient care and what the AMA is doing about it.

A report from the Guardian details how the VA removed language protecting patients from discrimination based on political affiliation and lifestyle. The department denies that there has been any actual change in policy.

Nonprofit Ascension Health announced its purchase of Amsurg, adding 250 outpatient surgery centers to its expanding portfolio. The Catholic-based hospital group said the move will allow it to focus more on community-based care by keeping more patient referrals in-house.

Lines included in the kits were misassembled and could result in a botched blood transfusion. Due to the risk of serious injury or death, the recall has been designated as Class I.

Endotracheal tubes inside Medline neonatal intubation kits have been deemed too narrow, putting newborn patients at risk for hypoxia. This recall has been given the most serious FDA designation due to the risk of death.

Some infusion systems manufactured by Zyno Medical were released with unapproved software that could cause safety features to malfunction. Use of any device subject to the recall is to cease immediately. 

Law firm Wright & Schulte said they filed a legal complaint on behalf of patients, pointing to the health system’s alleged lack of transparency and negligence in protecting data as the basis for the lawsuit.

On Monday a district judge in Massachusetts declared the Trump administration’s squashing of billions in NIH grants “void and illegal.” 

An exclusive interview with Hal Andrews, President and CEO of Trilliant Health, on the topic of price transparency and how regulators and companies can contain costs for patients.